Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience

Acta Orthopaedica Scandinavica, Supplement

Volumn 70, Issue 285, 1999, Pages 74-82

  Sæter, Gunnar ^a   Wiebe, Thomas ^b   Wiklund, Tom ^c   Monge, Odd ^d   Wahlqvist, Yngve ^e   Engström, Katarina ^f   Forestier, Erik ^g   Holmström, Teddy ^c   Stenwig, Anna E ^a   Willén, Helena ^b   Brosjö, Otte ^e   Follerås, Gunnar ^a   Alvegård, Thor A ^b   Strander, Hans ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g Umeå Regional Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE;

ADOLESCENT; ARTICLE; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PREOPERATIVE TREATMENT; SCHOOL CHILD; ADJUVANT CHEMOTHERAPY; BONE TUMOR; CHILD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; METHODOLOGY; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; REGISTER; SCANDINAVIA;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; OSTEOSARCOMA; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; REGISTRIES; SCANDINAVIA;

EID: 0032776604     PISSN: 03008827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bacci G, Picci P, Avella M, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother 1990; 2: 127-35.
2. Bacci G, Picci P, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 1993; 71: 1224-30.
3. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72: 3227-38.
4. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-5.
5. Bauer H C F. DNA cytometry of osteosarcoma. Acta Orthop Scandi 1988 Suppl 228, vol 59.
6. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996; 14: 848-58.
7. Bruland O S, Fodstad O, Aas M, et al. Immunoscintigraphy of bone sarcomas - Results in 5 patients. Eur J Cancer [A] 1994; 30A: 1484-9.
8. Bruland O S, Skretting A, Solheim O P, Aas M. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol. 1996; 35: 381-4.
9. Davis A M, Bell R S, Goodwin P J. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-31.
10. Delepine N, Delepine G, Cornille H, et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15: 489-94.
11. Ferrari S, Sassoli V, Orlandi M, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993; 5: 135-41.
12. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443-51.
13. Harvei S, Solheim Ø. The prognosis in osteosarcoma: Norwegian National data. Cancer 1981; 48: 1719-23.
14. Jaffe N, Paed D. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972; 30: 1627-31.
15. Kleinerman E S, Meyers P A, Raymond A K, et al. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother 1995; 17: 181-93.
16. Meyers P A, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
17. Rosen G, Caparros B., Huvos A G, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30.
18. Rosen G, Suwansirikul S, Kwon C, et al. High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 1974; 33:1151-63.
19. Saeter G. Treatment of osteosarcoma with high-dose methotrexate-containing neoadjuvant chemotherapy. Scandinavian Sarcoma Group data. Med Ped Oncol 1996a; 27: 263 (Abstract).
20. Saeter G. Treatment strategies and outcome in metastatic (relapsed) osteogenic sarcoma. The Scandinavian Sarcoma Group (SSG) experience. Med Ped Oncol 1996b; 27: 264 (Abstract).
21. Saeter G, Alvegård T A, Elomaa I, et al. Treatment of high-grade osteosarcoma of the extremities - the Scandinavian Sarcoma Group experience. Acta Orthop.Scand 1994; 65 (Suppl): 262: 77.
22. Saeter G, Høie J, Stenwig A E, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995; 75: 1084-93.
23. Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996; 56: 2434-39.
24. Smith M A, Ungerleider R S, Horowitz M E, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83: 1460-70.
25. Strander H, Bauer H C, Brosjo O, et al. Long-term adjuvant Interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995; 34: 877-80.
26. Sæter G, Alvegård T A, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-75.
27. Sæter G, Alvegård T A, Monge O R, et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997; 33: 1551-8.
28. Sæter G, Bruland O S. High-grade osteosarcoma (OS): the scope beyond the "classical" patient. In: Towards the eradication of osteosarcoma metastases: an Odyssey 1998; 21-23.
29. Sæter G, Bruland Ø S, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma. The Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol 1996; 35 (Suppl) 8: 129-34.
30. Sæter G, Talle K and Solheim Ø. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continous-infusion etoposide. Cancer Chemother Pharmacol 1995; 36: 172-5.